哌拉西林-他唑巴坦/美罗培南与黏菌素/美罗培南治疗碳青霉烯耐药肺炎克雷伯菌相关呼吸机相关性肺炎的比较
这是一项在ICU开展的随机、开放标签临床试验,计划纳入88例确诊碳青霉烯耐药肺炎克雷伯菌(CRKP)相关呼吸机相关性肺炎(VAP)患者,随机接受美罗培南/哌拉西林-他唑巴坦或美罗培南/黏菌素治疗。主要终点为基线至第7天临床肺部感染评分(CPIS)变化、ICU住院时长和无呼吸机天数,次要终点包括28天死亡率、细菌清除及肝肾功能不良事件。该研究旨在为双β-内酰胺方案治疗CRKP相关VAP提供证据。
要点
- 拟纳入88例ICU确诊CRKP相关VAP患者,随机接受美罗培南/哌拉西林-他唑巴坦或美罗培南/黏菌素。
- 主要终点为基线至第7天CPIS变化、ICU住院时长和无呼吸机天数。
- 次要终点包括28天死亡率、细菌清除及肾或肝不良事件。
核心结论
- 该研究旨在为双β-内酰胺方案美罗培南/哌拉西林-他唑巴坦对比美罗培南/黏菌素治疗CRKP相关VAP提供有力证据,以弥补研究空白并改进ICU中VAP管理的临床指南。
研究设计与样本
- 随机、开放标签临床试验,计划纳入88例ICU确诊CRKP相关VAP患者,随机分配至美罗培南/哌拉西林-他唑巴坦组或美罗培南/黏菌素组。
- 随机化和数据收集遵循SPIRIT 2013指南。
- 试验已在伊朗临床试验注册中心(IRCT)注册,ID为IRCT20240229061132N1,注册日期为2025年3月16日。
主要发现
- 原文为试验方案,未报告研究结果。
关键数值与推荐
- 主要结局为基线至第7天临床肺部感染评分(CPIS)变化、ICU住院时长和无呼吸机天数。
- 次要结局包括28天死亡率、细菌清除以及肾或肝不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ventilator-associated pneumonia (VAP) is a major concern in ICUs, particularly with carbapenem-resistant Klebsiella pneumoniae (CRKP). Dual beta-lactam antibiotic regimens may improve outcomes compared to traditional therapies. This study evaluates the efficacy and safety of meropenem/piperacillin-tazobactam versus meropenem/colistin for CRKP-related VAP. Primary outcomes are the change in Clinical Pulmonary Infection Score (CPIS) from baseline to Day 7, ICU length of stay, and ventilator-free days. Secondary outcomes include 28-day mortality, bacterial clearance, and renal or hepatic adverse events. METHODS: This randomized, open-label clinical trial will enroll 88 ICU patients with confirmed CRKP-related VAP. Participants will be randomly assigned to receive either meropenem/piperacillin-tazobactam or meropenem/colistin. The primary endpoints are improvement in CPIS, ICU length of stay, and ventilator-free days. Secondary endpoints include bacterial clearance and clinical recovery over 28 days. Safety will be assessed via renal and hepatic function monitoring and adverse event recording. Randomization and data collection follow SPIRIT 2013 guidelines to ensure rigor and transparency. DISCUSSION: Studies indicate that antibiotic combinations, particularly dual beta-lactam therapies, may enhance efficacy against resistant pathogens, including CRKP. While limited studies exist on dual beta-lactam regimens, recent findings suggest promising outcomes with combinations like meropenem/piperacillin-tazobactam. This study aims to provide robust evidence to address the gap in research and improve clinical guidelines for VAP management in ICU settings. TRIAL REGISTRATION: This trial was registered in the Iranian Registry of Clinical Trials (IRCT; available at https://irct.behdasht.gov.ir/ ; ID: IRCT20240229061132N1). Registered on March 16, 2025.
引用
- Shadravan MM, Javandoust Gharehbagh F, Pourhoseingholi MA, et al. Piperacillin-tazobactam/meropenem vs colistin/meropenem for carbapenem-resistant Klebsiella Pneumoniae-related ventilator-associated pneumonia. Trials. 2026. PMID: 41514364. doi:10.1186/s13063-026-09425-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。